Table 3 Analysis of prognostic factors influencing overall survival and progression-free survival since diagnosis in LD-SCLC

Sex

 Male

Ref.

Ref.

 Female

0.7 (0.4–1.3)

0.23

0.8 (0.4–1.8)

0.63

0.7 (0.4–1.3)

0.22

0.6 (0.3–1.3)

0.22

 Age

1.0 (1.0–1.1)

0.74

1.0 (1.0–1.1)

0.81

1.0 (1.0–1.0)

0.90

1.0 (1.0–1.0)

0.87

Karnofsky

 80–100

Ref.

Ref.

 < 80

1.5 (0.8–2.9)

0.19

1.4 (0.7–3.0)

0.37

1.1 (0.6–2.1)

0.69

0.7 (0.3–1.6)

0.46

T-Classification

 T1

Ref.

Ref.

 T2

0.8 (0.2–2.9)

0.75

0.6 (0.1–2.7)

0.48

1.4 (0.4–5.0)

0.58

1.3 (0.3–5.9)

0.75

 T3

0.5 (0.2–1.6)

0.28

0.5 (0.2–1.8)

0.32

0.8 (0.3–2.4)

0.65

0.8 (0.2–3.0)

0.79

 T4

0.9 (0.3–2.1)

0.73

0.6 (0.2–1.7)

0.31

1.8 (0.7–4.9)

0.24

1.6 (0.5–5.2)

0.41

N-Classification

 N0

Ref.

Ref.

 N1

0.5 (0.1–2.5)

0.38

0.9 (0.2–5.6)

0.95

0.5 (0.1–1.8)

0.26

0.5 (0.1–2.4)

0.40

 N2

1.4 (0.5–3.7)

0.53

1.9 (0.6–5.9)

0.24

0.9 (0.4–2.3)

0.86

0.8 (0.3–2.2)

0.63

 N3

1.4 (0.5–3.8)

0.56

2.6 (0.7–9.2)

0.14

1.4 (0.5–3.5)

0.54

1.5 (0.5–4.6)

0.50

Start during cycle

 Early start

Ref.

Ref.

 Late start

0.9 (0.4–1.7)

0.66

0.9 (0.4–2.0)

0.73

0.8 (0.4–1.6)

0.62

1.0 (0.5–2.2)

0.99

 Very late start

0.3 (0.1–1.3)

0.10

0.2 (0.0–1.1)

0.06

0.4 (0.1–1.2)

0.09

0.3 (0.1–1.0)

0.05